Dayvigo (Lemborexant) Cost in North Carolina 2026: Prices, Insurance, Savings

In December 2019, the FDA approved lemborexant, marketed as Dayvigo, for treating insomnia in adults who struggle with sleep onset, sleep maintenance, or both. The drug is an oral dual orexin receptor antagonist (DORA). Lemborexant is available in 5 mg and 10 mg tablets, with dosing occurring once per night, and carries Schedule IV controlled substance classification. While lemborexant and suvorexant (Belsomra) both represent FDA-approved DORAs that work through the same mechanism, they are distinct medications often discussed in comparison.

What is established: Dayvigo has a manufacturer list price that is set by Eisai and is not fixed by federal law; what a North Carolina patient actually pays depends on insurance status, pharmacy benefit manager contracts, and whether a manufacturer savings program applies. What is not established from the sources available for this review: a single, current cash price or copay figure that applies statewide. Any specific dollar amount quoted online, including on this page's earlier draft, should be treated as a snapshot that can be wrong by the time you read it, and should be confirmed directly with a pharmacy, your insurer, or Eisai's savings program before you rely on it.

The real question is not "what does it cost" but "which pathway applies to you"

The useful question for a North Carolina reader is not "what is the Dayvigo price" in the abstract. It is which of four cost pathways applies to your situation, because each one produces a very different number:

1. Commercially insured, Dayvigo covered on your formulary (usually with prior authorization)
2. Commercially insured, but Dayvigo is non-preferred or requires a failed trial of another agent first
3. Enrolled in NC Medicaid or Medicare Part D
4. Uninsured and paying cash, either for the branded product or a compounded version

Because pharmacy pricing, insurer formularies, and Medicaid preferred drug lists change throughout the year, none of the specific figures below should be treated as durable. They are described qualitatively where a firm number cannot be verified from evidence available for this draft.

What determines the list price and why it differs from what you pay

Eisai sets a wholesale acquisition cost (WAC) for Dayvigo, and that WAC is what most "manufacturer list price" figures you see online are based on. The WAC is not the price most insured patients pay, because pharmacy benefit managers negotiate rebates and because manufacturer savings cards can offset a patient's copay. The FDA-approved prescribing information does not itself set a price; it documents the approved indication, dosing, and safety information, and is the correct place to verify the approved label rather than a pricing source (FDA label, accessdata.fda.gov; FDA approval letter, December 2019).

If you want a current number, the reliable sources are a direct pharmacy quote at the counter, your insurer's member portal showing your specific copay tier, or Eisai's own savings program page, checked on the day you plan to fill the prescription. A number pulled from a general web search or an older article, including prior versions of this page, may already be stale.

Does North Carolina Medicaid cover Dayvigo?

State Medicaid preferred drug lists (PDLs) are reviewed and updated on a recurring schedule, and coverage of a specific branded insomnia drug like Dayvigo can change between review cycles. Medicaid programs generally require patients to try lower-cost generic agents (such as zolpidem or trazodone) before approving a non-preferred branded drug, and orexin receptor antagonists have historically been placed in this non-preferred category by many state Medicaid programs. Whether that specific pattern currently holds for NC Medicaid is a fact that must be verified against the state's current PDL at the time you need coverage, since this draft cannot confirm the present-day status with a checkable primary source. If your plan denies coverage, ask your prescriber's office about a prior authorization exception request, which typically requires documenting a failed trial of a preferred agent.

Commercial insurance and prior authorization

Commercial insurers commonly place non-preferred brand-name insomnia drugs, including Dayvigo, behind a step-therapy requirement: try one or more generic agents first, and only approve the brand if those fail or are contraindicated. This is a general pattern in U.S. pharmacy benefit design, not a North Carolina-specific rule, and the details (which agents count as "preferred," how long a trial must last, whether appeals succeed) vary by plan and change over time. If your plan denies an initial request, ask your prescriber to document prior medication trials, their duration, and the reason each was stopped; that documentation is the standard basis for a successful appeal, though approval is not guaranteed.

The Eisai savings card: what is verifiable and what is not

Manufacturer copay savings programs are a standard part of how branded prescription drugs are marketed in the United States, and Eisai has offered a Dayvigo copay savings program in the past. The general structure of these programs, a card that reduces a commercially insured patient's copay and that explicitly excludes patients on government insurance such as Medicare, Medicaid, TRICARE, or VA benefits, is standard across the pharmaceutical industry and is consistent with how these programs are typically designed. The specific dollar cap, annual maximum, and enrollment requirements for Dayvigo's program should be confirmed directly on Eisai's current savings program page before you rely on a specific figure, since manufacturer program terms are revised periodically and are not something this review can verify as current.

Patients without any insurance do not qualify for a copay card model like this. If cost is a barrier and you have no insurance, ask your prescriber's office whether a manufacturer patient assistance program (income-based, providing the drug at no cost to qualifying patients) is currently active for Dayvigo, and verify the income threshold directly with the program rather than relying on a cited percentage of the federal poverty level.

Compounded lemborexant: legal status and the trade-off

Compounded lemborexant can be legally prepared by a licensed 503A compounding pharmacy under federal law (Section 503A of the Food, Drug and Cosmetic Act) and applicable state pharmacy board rules, provided the pharmacy holds a valid license and fills the prescription for a specific named patient based on an individual prescriber's order. This is different from a 503B outsourcing facility, which compounds without patient-specific prescriptions but must register with the FDA and follow current good manufacturing practice standards (FDA, Compounding and the FDA: Questions and Answers).

Compounded lemborexant is not FDA-approved. The clinical trials that established lemborexant's efficacy and safety used the commercially manufactured Eisai tablet, not a compounded preparation, and bioavailability or consistency between a compounded version and the approved product has not been independently established in published data available for this review. The FDA states plainly that compounded drugs are not FDA-approved and that patients should understand they carry additional risks compared with an approved product. If cost is the main obstacle to treatment, discuss the compounded option with your prescriber as one alternative among several, not as a default substitute, and weigh the savings against the lack of an independent bioequivalence check.

Telehealth prescribing in North Carolina

North Carolina permits prescribers to establish a valid patient-provider relationship through a synchronous audio-video telehealth visit and to prescribe controlled substances, including Schedule IV medications like Dayvigo, based on that visit. Federal telehealth prescribing flexibilities for controlled substances have been extended and modified multiple times since 2020; the exact rules in effect for 2026, including whether an in-person visit is ever required first, should be confirmed against current DEA guidance rather than assumed to be unchanged from a prior year (FDA, Drug Safety and Availability).

A reasonable telehealth visit for insomnia should include a sleep history, screening for obstructive sleep apnea and other conditions that mimic or worsen insomnia, and a discussion of cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before or alongside medication, consistent with sleep medicine guideline recommendations that favor CBT-I over long-term pharmacotherapy where access allows.

How Dayvigo compares to other insomnia medications

Generic zolpidem and generic trazodone are the lower-cost agents most Medicaid programs and commercial step-therapy protocols require patients to try before approving a branded DORA. Suvorexant (Belsomra) is the other FDA-approved orexin receptor antagonist; a generic version of suvorexant has entered the market, which has generally reduced its cost compared to the brand. Lemborexant and suvorexant work through the same general mechanism, blocking orexin signaling that promotes wakefulness, rather than enhancing GABA signaling the way benzodiazepines and Z-drugs (like zolpidem) do. Head-to-head comparative data between lemborexant and suvorexant on efficacy magnitude exist in the trial literature, but specific numeric comparisons should be checked against the primary trial publications rather than repeated from a secondary summary, since this review could not independently verify a specific effect-size comparison from a confirmed source.

Verification checklist: stable facts vs. facts that change month to month

Use this checklist to separate what you can treat as settled from what you must re-check before making a coverage or purchasing decision.

Stable facts (federal regulatory and clinical record; unlikely to change without a formal FDA or DEA action):

• Dayvigo (lemborexant) received FDA approval in December 2019 for adult insomnia.
• It is a dual orexin receptor antagonist, distinct in mechanism from benzodiazepines and Z-drugs.
• It is available as 5 mg and 10 mg tablets, taken once nightly.
• It is a Schedule IV controlled substance under federal law.
• Compounded versions are not FDA-approved and lack independent bioequivalence data versus the branded tablet.
• 503A compounding requires a patient-specific prescription; 503B facilities do not, but must follow FDA cGMP rules.

Volatile facts you must re-verify at the time of your decision (these can shift month to month or with each insurer's plan year):

• Eisai's current wholesale acquisition cost (WAC) and whether it has changed since this article's publish date.
• Your specific pharmacy's cash price for a 30-day supply, which varies by store and by discount program used.
• NC Medicaid's current preferred drug list status for lemborexant and which alternatives it requires first.
• Your specific commercial plan's tier placement, prior authorization criteria, and step-therapy requirements for Dayvigo.
• The Eisai savings card's current eligibility rules, annual maximum, and enrollment process.
• Whether a manufacturer patient assistance program is currently accepting applications and its income threshold.
• Current DEA telehealth prescribing rules for controlled substances, which have changed more than once since 2020.
• Whether your chosen 503A pharmacy is licensed in North Carolina and in good standing with the NC Board of Pharmacy.

Before you fill a prescription or budget for treatment, confirm each volatile item directly with the source that owns it (your pharmacy, your insurer, NC Medicaid, or Eisai), not from a general article.

Evidence boundary

Established: Dayvigo's FDA approval, indication, dosing forms, and controlled-substance schedule; the legal framework distinguishing 503A and 503B compounding; the general existence of manufacturer copay programs and their standard exclusion of government-insured patients; the general practice of step therapy and prior authorization for non-preferred branded drugs across commercial insurers.

Plausible but not verifiable from the sources used in this review: specific current dollar figures for Dayvigo's list price, average NC cash price, typical commercial copay, or savings card annual maximum; the current NC Medicaid preferred drug list status for lemborexant; specific approval or appeal-success rates for prior authorization requests.

Not established here: any head-to-head clinical superiority claim between lemborexant and suvorexant expressed as a specific number, and any quotation attributed to a named physician, since no verifiable source for such a quotation was available for this draft.